Atezolizumab,Talazoparib
roche,pfizer
['lung', 'lcsm,(-blcsm)', 'sclc']
patients with slfn11-expressing sclc may benefit from immune checkpoint inhibitor plus parp inhibitor #lcsm #lungcancer #sclc #oncology #asco23
News and views from the world of clinical oncology and hematology